Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
HGH 191AA16 residuesYLRIVQCRSVEGSCGFEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: HGH, rHGH, somatropin
One IU of somatropin costs anywhere from $4 on the gray market to $60 at a brand-name pharmacy. HGH 191AA is the full 191-amino-acid recombinant human growth hormone, identical to what the pituitary gland produces. Multiple FDA-approved brand versions exist (Norditropin, Genotropin, Omnitrope), though most community users source compounded or research-grade product. Clinical GHD replacement runs 0.3 to 1.5 IU per day. Community anti-aging and body recomposition protocols push 2 to 4 IU daily, well above clinical dosing. Sleep and recovery improvements show up in the first two weeks; visible fat loss takes six to ten weeks of consistent use.
Sleep gets deeper within days. That's the first thing most users notice after starting HGH 191AA, the full-length 191-amino-acid recombinant human growth hormone (somatropin, CAS 12629-01-5). The compound is bioidentical to endogenous GH produced by the anterior pituitary. Unlike secretagogues such as ipamorelin or CJC-1295 that signal the pituitary to release stored GH, exogenous somatropin bypasses the signaling chain entirely. Each injection delivers a known quantity of growth hormone directly into circulation. Subcutaneous bioavailability runs 70 to 80 percent [1], with peak serum levels at 3 to 5 hours post-injection. The FDA has approved multiple somatropin brands for adult growth hormone deficiency (GHD). Norditropin's 2023 prescribing information recommends starting at 0.1 to 0.5 mg per day, titrated to normalize IGF-1 for age and sex. Community protocols run considerably higher. Across r/PEDs, bodybuilding forums, and anti-aging communities, 2 to 4 IU per day (667 to 1333 mcg) is the standard body-recomposition dose, with advanced users pushing 4 to 6 IU. Real-world results track a predictable pattern: sleep improvement in weeks 1 to 2, recovery gains by week 3, visible fat loss by weeks 6 to 10, and peak body composition changes at weeks 9 to 16. Insulin resistance is the main metabolic risk above 2 IU per day. Fasting glucose can rise 10 to 20 mg/dL, making regular blood work non-optional at any dose.
Somatropin binds the growth hormone receptor (GHR), a type I cytokine receptor found on hepatocytes, adipocytes, myocytes, and chondrocytes. Receptor dimerization activates the JAK2-STAT5 signaling cascade. This triggers transcription of IGF-1 in the liver, which mediates most of the downstream anabolic and metabolic effects. The lipolytic pathway is direct and GH-receptor-dependent. GH activates hormone-sensitive lipase in adipose tissue, breaking down stored triglycerides into free fatty acids. This is why morning fasted dosing is popular in community protocols; it amplifies the fat-mobilizing window before carbohydrate intake blunts the effect. GH also stimulates chondrocyte proliferation and collagen synthesis in connective tissue. Bone mineral density improvements are measurable by dual-energy X-ray absorptiometry at six months of continuous use. Protein synthesis in skeletal muscle increases through both direct GHR activation and IGF-1-mediated mTOR pathway signaling. The negative feedback loop matters. Exogenous GH suppresses hypothalamic GHRH secretion and upregulates somatostatin release. This blunts endogenous pulsatile GH output during use; periodic off-cycles allow the hypothalamic-pituitary axis to recover its natural rhythm.
Exogenous recombinant somatropin is the gold-standard, FDA-approved treatment for adult GHD with strong Phase 3 evidence. Off-label body-composition and anti-aging use shows real but modest benefits in healthy adults. Performance-enhancement evidence is weak despite clear anabolic mechanism.
Norditropin (somatropin) FDA Prescribing Information (2023); NCBI Bookshelf: Somatropin for Growth Hormone Deficiency (NBK596750); Frontiers Endocrinology: Titrating GH Dose to High-Normal IGF-1 (2020)
High-quality RCTs cover diagnosed GHD populations almost exclusively. Healthy-adult body-composition trials are small and short-duration. Long-term safety of supraphysiological dosing (community 2–6 IU/day) is not formally studied. Cancer risk via sustained IGF-1 elevation is a real concern with chronic high-dose use.
Universally regarded as the most reliable and direct GH elevation method: preferred over secretagogues for predictability and potency. Heavy use across anti-aging, body-recomposition, and competitive bodybuilding communities.
Science firmly supports GHD-replacement dosing (0.3–1.5 IU/day). Community protocols routinely run 2–6 IU/day for body-composition purposes: 2–10× the clinical GHD starting dose. The anabolic mechanism is fully understood, but no high-quality RCTs exist in healthy adults at community-level doses. Real benefits are plausible and user-reported, but risk profile scales with dose.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 200mcg | Daily |
| Moderate | 500mcg | Daily |
| Aggressive | 1mg | Daily |
The IU-to-mcg conversion trips up most beginners: 1 IU equals roughly 333 mcg. A 10 IU vial holds about 3.3 mg of somatropin. A 15 IU vial holds roughly 5 mg. Reconstitution math for the standard 10 IU vial: add 1 mL bacteriostatic water. That gives you 10 IU per mL. On a U-100 insulin syringe, 10 units equals 1 IU (333 mcg). For the beginner dose of 200 mcg (0.6 IU), draw 6 units. Moderate dose of 500 mcg (1.5 IU) is 15 units. Aggressive dose of 1000 mcg (3 IU) is 30 units. Swirl the vial gently after adding water. Never shake or vortex somatropin; the protein is fragile and shaking creates dimers that increase side effects. Store reconstituted vials at 2 to 8 degrees Celsius and use within 28 days. Lyophilized (powder) vials also belong in the fridge. Never freeze reconstituted HGH. Morning fasted injection maximizes fat mobilization. Pre-bed injection amplifies the natural nocturnal GH pulse and tends to improve sleep quality. Split dosing (AM plus PM) is common at 3 IU per day or above.
Exogenous HGH suppresses endogenous pituitary GH secretion via negative feedback on GHRH and via somatostatin upregulation. Long-term continuous use blunts natural pulsatile GH secretion. Periodic off-cycles allow the hypothalamic-pituitary axis to recover, IGF-1 to normalize (reducing sustained cancer risk), and provide a monitoring window to detect glucose or metabolic changes. Antibody formation against exogenous GH is rare with high-purity preparations but can occur with gray-market products: an off-cycle allows detection if efficacy diminishes.
Or use the universal Peptide Calculator for any peptide.
Expected: Improved sleep quality (2–4 wk), skin elasticity (8–12 wk), mild fat loss (12–24 wk)
Monitor: IGF-1 at baseline, week 4, week 8, and cycle end. Fasting glucose monthly.
Gather supplies: one vial of lyophilized HGH 191AA, bacteriostatic water, a U-100 insulin syringe (29 or 31 gauge, 0.5 inch needle), and alcohol swabs.
Clean the top of both the HGH vial and the bacteriostatic water vial with alcohol swabs. Let them air dry.
Draw 1 mL (100 units on the syringe) of bacteriostatic water. For a 10 IU vial, this gives 10 IU per mL. For a 15 IU vial, this gives 15 IU per mL.
Inject the water slowly down the inside wall of the HGH vial. Do not spray it directly onto the powder. Let gravity pull the water down; tilt the vial if needed.
The solution should be clear. If it stays cloudy after five minutes, the product may be degraded. Do not use a cloudy solution.
For a 10 IU vial reconstituted with 1 mL: beginner 200 mcg (0.6 IU) equals 6 units; moderate 500 mcg (1.5 IU) equals 15 units; aggressive 1000 mcg (3 IU) equals 30 units.
Pinch a fold of skin on the abdomen (avoiding a 2-inch radius around the navel), thigh, or glute. Insert the needle at a 45 to 90 degree angle. Inject slowly. Rotate sites each injection.
Morning fasted for fat loss prioritization. Pre-bed for sleep quality and recovery. Split AM plus PM for doses above 3 IU per day.
Store the reconstituted vial upright in the refrigerator at 2 to 8 degrees Celsius. Use within 28 days. Do not freeze.
Reference route: no adjustment needed
Bioavailability ~70–80%. Slower absorption than IM but steady, sustained serum levels. Abdomen preferred; thigh and glute acceptable. Rotate injection sites systematically.
No dose adjustment required: bioavailability similar to SC
Faster Tmax than SC but similar total exposure. More painful. Not standard in clinical or community settings. Occasionally used by bodybuilders for convenience.
100% bioavailability vs ~70–80% SC; dose may need downward adjustment
Used in PK studies and hospital GHD diagnostic testing. Not appropriate for home or community use. Risk of rapid GH surge and acute side effects.
HGH raises hepatic IGF-1 production systemically; adding IGF-1 LR3 amplifies local downstream anabolic signaling directly in muscle tissue. Commonly cycled 4 weeks on / 4 weeks off within a longer HGH cycle to enhance muscle building without continuous supraphysiological IGF-1.
IGF-1 LR3 20–50 mcg post-workout SC, 4 weeks on / 4 weeks off
Occasionally added to exogenous HGH to preserve pulsatile GH signaling or as a lower-cost alternative layer. Largely redundant with exogenous HGH in place: some users prefer it as a replacement rather than a stack. If stacked, monitor IGF-1 closely as combined effect can be supraphysiological.
CJC-1295 No DAC + Ipamorelin blend pre-bed SC at reduced doses (100 mcg each); optional add-on only
Primarily used as an alternative to HGH for visceral fat reduction (FDA-approved for HIV-associated lipodystrophy). Rarely co-administered with HGH: used in place of it. If combined in advanced protocols, monitor IGF-1 closely.
Advanced bodybuilders combine insulin with HGH for extreme anabolism, but insulin + GH dramatically increases risk of life-threatening hypoglycemia. GH blunts insulin sensitivity (raising glucose), which can mask early hypoglycemic warning signs when exogenous insulin is co-administered. Not appropriate for beginners under any circumstances.
Do not combineSomatostatin directly inhibits GH secretion and opposes HGH's GH-receptor activity downstream. Co-administration negates HGH efficacy. Clinically used intentionally to block GH in acromegaly.
Do not combineOral estrogen reduces hepatic GH sensitivity and IGF-1 response significantly. May require 2× higher dose to achieve equivalent IGF-1 elevation. Transdermal estrogen has substantially less impact.
Chronic glucocorticoid use reduces GH efficacy and may unmask adrenal insufficiency: GH can impair cortisol synthesis. Patients on long-term steroids using HGH need adrenal function monitoring.
Pricing updated 2026-04-09
Insulin resistance is the most clinically important risk with HGH 191AA. At doses of 2 IU per day or higher, fasting blood glucose can rise 10 to 20 mg/dL. The Norditropin FDA label lists new-onset type 2 diabetes and impaired glucose tolerance as labeled adverse events. Fasting glucose monitoring is mandatory, especially in the first eight weeks. If fasting glucose consistently reaches 100 mg/dL, dose reduction or discontinuation is warranted. HbA1c should be checked at baseline and every three to six months on-cycle to catch cumulative glucose dysregulation. Carpal tunnel syndrome is fully dose-dependent. Numbness and tingling in the hands appear most often at 2 IU per day or above. The mechanism involves fluid retention in the carpal tunnel sheath compressing the median nerve. Symptoms typically resolve within two to four weeks after dose reduction. A wrist splint at night helps during acute episodes. Pushing through this symptom at higher doses risks nerve damage. Water retention and peripheral edema are common during the first four to eight weeks. Hands, feet, and face are the most affected areas. Sodium restriction and pre-bed timing (instead of morning injection) can reduce severity. This side effect generally stabilizes as the body adapts, but it's the primary quality-of-life complaint in early weeks. Supraphysiological IGF-1 is a real long-term concern. Chronically raised IGF-1 above age-normal ranges is associated with increased cancer risk and acromegalic changes (jaw thickening, extremity enlargement). IGF-1 labs are the single most important monitoring tool. Target the upper half of normal for age; avoid sustained levels above 350 ng/mL. Gray-market quality introduces additional risks that pharmaceutical-grade product doesn't carry. High dimer content (improperly bonded GH molecules) increases side effects while reducing efficacy. Bacterial endotoxins from poor manufacturing can cause injection-site reactions, fever, and systemic inflammation. This is not a hypothetical concern; it's the most common source of disproportionate side effects reported in community forums. Injection site lipohypertrophy (hardened lumps under the skin) develops when the same spot is used repeatedly. Rotating injection sites across abdomen quadrants, thighs, and glutes prevents this. Never inject the same location more than once per week. Thyroid function can shift during use. GH increases peripheral conversion of T4 to T3, which may drop Free T4 levels and unmask subclinical hypothyroidism. Anyone on levothyroxine should get a thyroid panel at baseline and mid-cycle. Contraindications: active malignancy or cancer history (GH promotes tumor growth via IGF-1), proliferative diabetic retinopathy, acute critical illness, Prader-Willi syndrome with severe obesity, known hypersensitivity to somatropin or metacresol preservative, and pregnancy or breastfeeding. These are absolute stop signs.
Verify HGH 191AA dosing and safety with a second opinion
"HGH 191AA" sold through gray-market research channels is entirely unregulated. Common issues include: mislabeled or underdosed vials, bacterial endotoxins from poor manufacturing, and high dimer content (two GH molecules improperly bonded: increases side effects, reduces efficacy). Certificate of Analysis claims are often unverifiable. Prescription compounded somatropin (503A pharmacy) or brand-name HGH substantially reduces this risk.
| Test | When | Target |
|---|---|---|
| IGF-1 (serum) | Baseline; every 4 weeks during titration; every 6–12 weeks at maintenance | Upper half of normal range for age/sex: approximately 150–300 ng/mL for adults 30–60 years; avoid sustained levels > 350 ng/mL |
| Fasting blood glucose | Baseline; weekly for first 8 weeks; monthly thereafter | < 100 mg/dL; investigate if consistently ≥ 100 mg/dL; discontinue if > 126 mg/dL |
| HbA1c | Baseline; every 3–6 months on-cycle; at cycle end | < 5.7% (pre-diabetic threshold) |
| Thyroid panel (TSH + Free T4) | Baseline; every 6 months | — |
| Lipid panel (total cholesterol, LDL, HDL, triglycerides) | Baseline; every 6 months | — |
Primary efficacy and safety biomarker: reflects integrated GH activity over days. Mandatory for dose titration. Supraphysiological IGF-1 is associated with cancer risk and acromegalic changes.
HGH causes clinically significant insulin resistance at doses ≥2 IU/day: fasting glucose can rise 10–20 mg/dL or more
Detects cumulative glucose dysregulation that spot fasting glucose alone may miss in longer cycles
GH increases peripheral T4-to-T3 conversion: Free T4 may fall, potentially unmasking subclinical hypothyroidism; adjust levothyroxine if on thyroid replacement
GHD is associated with unfavorable lipid profiles; HGH replacement typically improves LDL/HDL ratio: labs confirm expected benefit and detect any adverse lipid changes
Improved sleep depth and onset. Mild water retention and joint stiffness possible as the body adjusts. No visible body composition changes yet.
Energy and recovery noticeably improved. Skin begins to feel smoother and more hydrated. Mild carpal tunnel symptoms may appear at higher doses.
Fat loss becomes visible, especially around the midsection. Lean muscle fullness increases. Workout recovery time shortens. Nail and hair growth may accelerate.
Peak body composition changes. Skin elasticity and tone markedly improved. Joint comfort often improves despite initial stiffness. IGF-1 levels stabilize at an elevated baseline.
Long-term benefits in connective tissue repair, bone density, and immune function. Results are dose-dependent. Periodic blood work (IGF-1, fasting glucose) is recommended.
Weeks 1 to 2: Sleep changes come first. Most users notice deeper sleep and faster onset within the first few days of dosing. Serum GH rises immediately with each injection, and IGF-1 starts climbing within the first week or two. Mild water retention in the hands and feet is normal at this stage. Joint stiffness can appear at higher starting doses. No visible body composition changes yet. Weeks 3 to 4: Recovery is the next signal. IGF-1 approaches its steady-state level. Protein synthesis ramps up and lipolytic activity in fat tissue measurably increases. Workouts feel different because recovery times noticeably shorten. Skin starts to feel plumper and more hydrated. Carpal tunnel tingling may show up if you're running 2 IU per day or higher. Fasting glucose elevation becomes detectable on lab work. Weeks 5 to 8: Fat loss becomes visible. Lipolysis accelerates and fat mass starts declining, typically starting around the midsection and flanks. Muscle fullness and vascularity improve. Workout performance and strength trend upward. Water retention usually peaks in this window and then stabilizes. Carpal tunnel tends to be at its worst here at higher doses. Weeks 9 to 16: Peak body composition changes. Clinical trials in GHD patients documented 3 to 5 percent fat mass reduction in this timeframe. Skin elasticity and tone are markedly improved. Joints often feel better now despite the initial stiffness from earlier weeks. Nails and hair grow noticeably faster. Side effects generally diminish as the body adapts. Glucose management becomes the main monitoring priority. Weeks 16 to 24 and beyond: Long-term connective tissue benefits accumulate. Bone density improvements become measurable by DEXA scan around the six-month mark. Collagen synthesis continues, supporting joint and skin health. Body composition gains tend to plateau at a given dose. Diminishing returns past 24 weeks without a dose adjustment are common. Watch for any signs of acromegalic changes (jaw or brow thickening, hand or feet enlargement) with prolonged high-dose use.
Serum GH rises immediately with each dose. IGF-1 begins to elevate within 1–2 weeks. No measurable body composition changes at this stage.
Better sleep depth and faster sleep onset: often within days. Mild water retention in hands and feet. Joint fullness or stiffness at higher doses.
IGF-1 approaches steady state. Protein synthesis upregulated. Lipolytic activity in adipose tissue measurably increased.
Workout recovery noticeably faster. Skin begins to feel plumper and more hydrated. Carpal tunnel tingling may appear at doses ≥2 IU/day.
Adipose tissue lipolysis accelerates: fat mass begins to decline. Lean mass accretion starts. Metabolic rate increases.
Visible fat loss: midsection and flanks first. Muscle fullness and vascularity improve. Workout performance and strength trend up.
Significant body fat reduction (3–5% fat mass change documented in clinical trials). Lean mass preservation or mild gain. IGF-1 stable at elevated baseline.
Skin elasticity and tone markedly improved. Joint comfort often paradoxically improves despite initial stiffness. Nails and hair grow faster.
Bone density improvements measurable at 6 months+ (dual-energy X-ray absorptiometry). Connective tissue repair continues. Sustained IGF-1 elevation supports collagen synthesis.
Body composition plateau at same dose: diminishing returns past 24 weeks without dose adjustment. Connective tissue, skin, and joint benefits continue accumulating.
Source: SC terminal half-life from PK studies in healthy volunteers (PMID 11505794)
Loading the interactive decay curve.
Somatropin (HGH 191AA) is FDA-approved under multiple brand names including Norditropin (Novo Nordisk), Genotropin (Pfizer), Humatrope (Lilly), and the biosimilar Omnitrope (Sandoz). Approved indications include adult growth hormone deficiency, pediatric GHD, Turner syndrome, and several other conditions listed in the respective prescribing information. In the United States, somatropin is a prescription medication. Possession without a valid prescription is not federally scheduled but may violate state pharmacy laws. Distribution without a license is illegal. Compounded somatropin from a 503A pharmacy requires a prescription and a patient-practitioner relationship. Gray-market "HGH 191AA" sold as a research chemical occupies a legal gray area. These products are not FDA-regulated, not tested for purity or potency, and carry no manufacturing oversight. Quality varies dramatically by source. Somatropin is banned by WADA (World Anti-Doping Agency) at all times, both in competition and out of competition. Athletes subject to drug testing should be aware that GH detection windows have improved considerably. This content is for informational and research purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any peptide or hormone.
Peptide Schedule Research TeamReviewed Apr 20266 Citations
